CALC
CalciMedica, Inc.
Healthcare — Biotechnology
CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. The company also develops Auxora for the treatment of ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory and immunologic disease. The company is based in La Jolla, California.
Price History
Fundamentals
| Market Cap | $16.43M |
| P/E Ratio (TTM) | - |
| Forward P/E | -0.64 |
| EPS (TTM) | $-1.31 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -399.51% |
| Debt/Equity | - |
| Recommendation | Strong Buy 1.5 |
| Analyst Target | $10.33 |
| Analysts | 3 |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 56.1 |
| Beta | 1.24 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $7.20 |
| 52-Week Low | $0.46 |
| 50-Day Avg | $0.74 |
| 200-Day Avg | $2.28 |
| Avg Volume | $1.28M |
| Volume | 935.3K |
Performance Analysis
BULLISHCALC shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:01 UTC
Back to Screener Export Report